Direct inhibition of KRAS signaling with the KRASG12C-specific inhibitor ARS853 (Lito et al., 2016, Patricelli et al., 2016) in lung and colorectal cancer cell lines harboring KRASG12C mutations led to reductions in PD-L1 mRNA expression, but not in the KRASG12S A549 control lung cancer cell line (Figures 1D and 1E). Here, KRAS is linked to lung carcinoma.